Original ArticleAssessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system
Graphical Abstract
In this study, FeDCE NPs can be used as a probe to estimate the delivering and internalization in NSCLC by mMRI. Our FeDCE NPs potentially open a new avenue to identify the delivery efficacy and estimate concentration of drug by using mMRI (as shown in manuscript Figure 3, E). Moreover, FeDCE NPs induced apoptosis mechanism via inhibition of NF-κB mediated signaling pathway can be further validated by reporter gene system (as shown in manuscript Figure 6, B). In summary, this dual functional FeDCE NPs may serve both therapeutic effect and diagnostic utility in the same time in NSCLC.
Section snippets
Cell line and culture
An EGFR-overexpressing human lung adenocarcinoma cell line, CL1-5-F4, was used in this study.20 Cells were kindly provided by Dr. Chia-Lin Hsieh (Taipei Medical University, Taiwan). CL1-5-F4 and CL1-5-F4/NF-κB-luc2 cells were cultured in Dulbecco’s modified Eagle’s medium and Ham’s F-12 nutrient medium supplemented with 10% fetal bovine serum (GE Healthcare Life Sciences HyClone Laboratories, UT, USA) and 1% penicillin–streptomycin (Invitrogen, Carlsbad, CA, USA). The cells were maintained in a
Treatment effects of FeDC-E NPs on CL1-5-F4/NF-κB-luc2 lung cancer cells
To evaluate the cytotoxicity of erlotinib within FeDC-E NPs, we performed the MTT assay. FeDC-E NPs were found to exhibit dose-dependent cytotoxicity against CL1-5-F4/NF-κB-luc2 cells, with an erlotinib IC50 value of approximately 12.8 μM (Figure 1, A). Different concentrations of free erlotinib toxicity were also validated using the MTT assay (Figure 1, A). In addition, no cytotoxicity was observed in the group that received FeDC NPs alone (Figure 1, B). Cytotoxicity was only found in the
Discussion
In this study, we evaluated the uptake of FeDC-E NPs and their effect on the NF-κB-modulated antiapoptotic mechanism through iron-sensitive T2* MRI, NF-κB molecular imaging, and other molecular techniques (flow cytometry, Western blotting, and IHC) in NSCLC in vitro and in vivo. Our previous study suggested that FeDC-E NPs inhibited the migration and invasion of tumor cells through ERK-NF-κB signaling; however, the effect of FeDC-E NPs on the apoptotic mechanisms remains unclear.19 Nelson et al
Author contribution
All the authors participated in the design, interpretation of the data, drafting and review of the manuscript.
References (46)
- et al.
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003
Chest
(2005) - et al.
Magnetic resonance molecular imaging with nanoparticles
J Nucl Cardiol
(2004) - et al.
BCL-2 expression is prognostic for improved survival in non-small cell lung cancer
J Thorac Oncol
(2009) - et al.
Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer
Ann Thorac Surg
(2006) - et al.
Temporal control of NF-kappaB activation by ERK differentially regulates interleukin-1beta-induced gene expression
J Biol Chem
(2004) - et al.
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications
Biomaterials
(2005) - et al.
Cancer statistics, 2009
CA Cancer J Clin
(2009) - et al.
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
Cancer Res
(1993) - et al.
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival
Clin Cancer Res
(2001) - et al.
Erlotinib in previously treated non-small-cell lung cancer
N Engl J Med
(2005)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
J Clin Oncol
Molecular magnetic resonance imaging
Biomed Imaging Interv J
MR quantification of hepatic iron concentration
Radiology
Principles, techniques, and applications of T2*-based MR imaging and its special applications
Radiographics
Using NF-kappaB as a molecular target for theranostics in radiation oncology research
Expert Rev Mol Diagn
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target
Front Biosci (Landmark Ed)
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
Cell Death Dis
Copy-number variation of MCL1 predicts overall survival of non-small-cell lung cancer in a Southern Chinese population
Cancer Med
Opposing effects of bortezomib-induced nuclear factor-kappaB inhibition on chemical lung carcinogenesis
Carcinogenesis
Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent MCL-1 protein cleavage
Oncogene
Erlotinib-conjugated iron oxide nanoparticles as a smart cancer-targeted theranostic probe for MRI
Sci Rep
Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line
Am J Respir Cell Mol Biol
Sorafenib inhibits TPA-induced MMP-9 and VEGF expression via suppression of ERK/NF-kappaB pathway in hepatocellular carcinoma cells
In Vivo
Cited by (24)
Recent trends and advances in nanosystems with tyrosine kinase inhibitors for image-guided cancer treatments
2023, Journal of Drug Delivery Science and TechnologyEngineered nanoparticles as emerging gene/drug delivery systems targeting the nuclear factor-κB protein and related signaling pathways in cancer
2022, Biomedicine and PharmacotherapyCitation Excerpt :Fe3O4 NPs display excellent magnetic characteristics and have been applied as a contrast agent in MRI. NF-κB inhibitor-loaded Fe3O4 NP as a theranostic tool can simultaneously suppress the NF-κB pathway and is also used as an imaging contrast agent to track NPs internalization through MRI [176]. SLNs-based nanocarriers are excellent systems for the encapsulating and delivery of highly hydrophobic drugs such as curcumin.
Protein kinase inhibitors and cancer targeted therapy
2022, Protein Kinase Inhibitors: From Discovery to TherapeuticsRegorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer
2020, Biomedicine and PharmacotherapyCitation Excerpt :CT26 and HT29 cells were seeded in 12 wells plate with 2 × 105 cells and incubated overnight. Cells were treated with 0, 10 or 20 μM regorafenib for 24 h. Then, to investigate the activation of caspase-3, -8 or -9, cells were followed with CaspGlow Fluorescein Active Caspase-3, -8 or -9 Staining procedure, respectively (BioVision, Milpitas, CA, USA) [20,21]. CT26 and HT29 cells were seeded in 12 wells plate with 2 × 105 cells and incubated overnight.
Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model
2020, Biomedicine and PharmacotherapyDelivery of erlotinib for enhanced cancer treatment: An update review on particulate systems
2020, Journal of Drug Delivery Science and Technology
Source of funding: We thank the Ministry of Science and Technology and Ministry of Health and Welfare of the Republic of China for their support (MOST 104-2314-B-038-051 MY3). The study was supported by Taipei Medical University and Taipei Medical University Hospital (grant nos. 104TMU-TMUH-23, TMU105-AE1-B49, 104TMUH-SP-02, 105TMUH-SP-01, and 105TMU-TMUH-23) and the Health and Welfare Surcharge on Tobacco Products (grant no. MOHW105-TDU-B-212-134001). This project was also supported by the National Health Research Institutes (MG-105-SP-07, MG-106-SP-07).
Conflict of interest: All authors have no conflicts of interest to declare.